Pricing Log in Create free account

Apimeds Pharmaceuticals US, Inc. (APUS) vs Gelteq Limited (GELS)

Apimeds Pharmaceuticals US, Inc. and Gelteq Limited are both Drug Manufacturers Specialty & Generic companies. Apimeds Pharmaceuticals US, Inc. is the larger, with a market value of $6.6M against $4.6M — 1.4× the size. Across the 8 metrics below, Gelteq Limited leads on 6 and Apimeds Pharmaceuticals US, Inc. on 2.

Valuation

Metric APUS GELS Drug Manufacturers Specialty & Generic median
P/E n/m — 19.25
P/S n/m — 2.11
P/B 0.07 n/m 1.78
Price to free cash flow n/m n/m 16.14
EV/EBITDA n/m n/m 12.58
EV/Sales n/m n/m 2.73
Earnings yield (905.20%) — (4.38%)
Free cash flow yield (192.65%) 0.00% 0.00%

Profitability

Metric APUS GELS Drug Manufacturers Specialty & Generic median
Gross margin — — 53.94%
Operating margin 0.00% — 0.00%
Net margin 0.00% — 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (100.13%) 0.00% (0.40%)
Return on assets (84.20%) 0.00% (3.32%)
Return on invested capital (15.96%) 0.00% 0.00%

Growth

Metric APUS GELS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — — 10.01%
EPS growth (last fiscal year) (205.56%) (62.07%) 49.06%
Revenue growth, 5-year CAGR — — 6.74%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric APUS GELS Drug Manufacturers Specialty & Generic median
Debt to equity 0.08 0.36 0.05
Current ratio 0.51 0.09 2.31
Net debt to EBITDA 0.38 (0.91) 0.97

Dividend

Metric APUS GELS Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.57%
Payout ratio — — 0.27

Size

Metric APUS GELS Drug Manufacturers Specialty & Generic median
Market cap 6.62m 4.61m 276.90m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack